Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H1 2020

June 2020 | 158 pages | ID: TDEF22552157EN
Global Markets Direct

Abstracts

Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H1 2020

SUMMARY

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) pipeline Target constitutes close to 46 molecules. Out of which approximately 38 molecules are developed by companies and remaining by the universities/institutes. The latest report Transient Receptor Potential Cation Channel Subfamily V Member 1 – Pipeline Review, H1 2020, outlays comprehensive information on the Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) – The transient receptor potential cation channel subfamily V member 1 (TrpV1) is a protein encoded by the TRPV1 gene. It belongs to a sub-family of the transient receptor potential protein group. It mediates proton influx and may be involved in intracellular acidosis in nociceptive neurons. It is involved in mediation of inflammatory pain and hyperalgesia. It sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. It is activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. It acts as ionotropic endocannabinoid receptor with central neuromodulatory effects.

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 8, 3, 14 and 8 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 6 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Dermatology, Metabolic Disorders, Cardiovascular, Ophthalmology, Gastrointestinal, Immunology, Genetic Disorders, Oncology and Respiratory which include indications Neuropathic Pain (Neuralgia), Pain, Osteoarthritis Pain, Cancer Pain, Diabetic Peripheral Neuropathy, Ocular Pain (Eye Pain), Postherpetic Neuralgia, Pruritus, Inflammatory Pain, Keratoconjunctivitis Sicca (Dry Eye), Visceral Pain, Alzheimer's Disease, Atopic Dermatitis (Atopic Eczema), Autoimmune Hepatitis, Blepharospasm, Breast Cancer, Cardiomegaly, Cardiovascular Disease, Chronic Heart Failure, Cluster Headache Syndrome (Cluster Headache), Congestive Heart Failure (Heart Failure), Cough, Crohn's Disease (Regional Enteritis), Demyelinating Diseases, Hypertension, Infantile Spasm (West Syndrome), Inflammation, Insomnia, Irritable Bowel Syndrome, Ischemia Reperfusion Injury, Myocardial Infarction, Non-Alcoholic Steatohepatitis (NASH), Ocular Hypertension, Ocular Inflammation, Open-Angle Glaucoma, Parkinson's Disease, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Post-Operative Pain, Prostate Cancer, Psoriasis, Radiculopathy, Schizophrenia, Skin Inflammation, Squamous Cell Carcinoma, Tremor, Tuberous Sclerosis and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
• The report reviews Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Overview
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Development
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Assessment
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Companies Involved in Therapeutics Development
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Drug Profiles
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Dormant Products
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Discontinued Products
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AlzeCure Pharma AB, H1 2020
Pipeline by Amorepacific Corp, H1 2020
Pipeline by AntalGenics SL, H1 2020
Pipeline by Astellas Pharma Inc, H1 2020
Pipeline by Bsense Bio Therapeutics Ltd, H1 2020
Pipeline by Centrexion Therapeutics Corp, H1 2020
Pipeline by Cmxtwenty, H1 2020
Pipeline by Concentric Analgesics Inc, H1 2020
Pipeline by GB Sciences Inc, H1 2020
Pipeline by GBSciences Inc, H1 2020
Pipeline by Grunenthal GmbH, H1 2020
Pipeline by GW Pharmaceuticals Plc, H1 2020
Pipeline by Interventional Analgesix Inc, H1 2020
Pipeline by Ion Channel Pharmacology LLC, H1 2020
Pipeline by Jeil Pharmaceutical Co Ltd, H1 2020
Pipeline by Medifron DBT Co Ltd, H1 2020
Pipeline by Mestex AG, H1 2020
Pipeline by Neurim Pharmaceuticals Ltd, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Oblique Therapeutics AB, H1 2020
Pipeline by Pila Pharma AB, H1 2020
Pipeline by Revive Therapeutics Ltd, H1 2020
Pipeline by Scopus BioPharma Inc, H1 2020
Pipeline by Serentrix LLC, H1 2020
Pipeline by Sorrento Therapeutics Inc, H1 2020
Pipeline by Sylentis SAU, H1 2020
Pipeline by Vitality Biopharma Inc, H1 2020
Pipeline by Winston Pharmaceuticals Inc, H1 2020
Pipeline by Young BioPharma LLC, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Dormant Products, H1 2020 (Contd..3), H1 2020
Dormant Products, H1 2020 (Contd..4), H1 2020
Dormant Products, H1 2020 (Contd..5), H1 2020
Dormant Products, H1 2020 (Contd..6), H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

AlzeCure Pharma AB
Amorepacific Corp
AntalGenics SL
Astellas Pharma Inc
Bsense Bio Therapeutics Ltd
Centrexion Therapeutics Corp
Cmxtwenty
Concentric Analgesics Inc
GB Sciences Inc
GBSciences Inc
Grunenthal GmbH
GW Pharmaceuticals Plc
Interventional Analgesix Inc
Ion Channel Pharmacology LLC
Jeil Pharmaceutical Co Ltd
Medifron DBT Co Ltd
Mestex AG
Neurim Pharmaceuticals Ltd
Novartis AG
Oblique Therapeutics AB
Pila Pharma AB
Revive Therapeutics Ltd
Scopus BioPharma Inc
Serentrix LLC
Sorrento Therapeutics Inc
Sylentis SAU
Vitality Biopharma Inc
Winston Pharmaceuticals Inc
Young BioPharma LLC